| mRNA |
PLX4720 |
CTRPv2 |
pan-cancer |
AAC |
0.0072 |
0.8 |
| mRNA |
dabrafenib |
CTRPv2 |
pan-cancer |
AAC |
0.0099 |
0.8 |
| mRNA |
KH-CB19 |
CTRPv2 |
pan-cancer |
AAC |
0.0092 |
0.9 |
| mRNA |
BRD-K75293299 |
CTRPv2 |
pan-cancer |
AAC |
-0.014 |
0.9 |
| mRNA |
BRD9876:MK-1775 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.023 |
0.9 |
| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0072 |
0.9 |
| mRNA |
BRD-K55473186 |
CTRPv2 |
pan-cancer |
AAC |
0.0089 |
0.9 |
| mRNA |
linifanib |
CTRPv2 |
pan-cancer |
AAC |
-0.0066 |
0.9 |
| mRNA |
ML334 diastereomer |
CTRPv2 |
pan-cancer |
AAC |
0.0075 |
0.9 |
| mRNA |
MGCD-265 |
CTRPv2 |
pan-cancer |
AAC |
-0.0056 |
0.9 |